AU2088800A - Method and diagnostic kit for diagnosis of endometriosis - Google Patents
Method and diagnostic kit for diagnosis of endometriosis Download PDFInfo
- Publication number
- AU2088800A AU2088800A AU20888/00A AU2088800A AU2088800A AU 2088800 A AU2088800 A AU 2088800A AU 20888/00 A AU20888/00 A AU 20888/00A AU 2088800 A AU2088800 A AU 2088800A AU 2088800 A AU2088800 A AU 2088800A
- Authority
- AU
- Australia
- Prior art keywords
- cd45ro
- hladr
- cd45ra
- endometriosis
- cd2o
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 123
- 238000000034 method Methods 0.000 title claims abstract description 26
- 238000009007 Diagnostic Kit Methods 0.000 title claims description 8
- 238000003745 diagnosis Methods 0.000 title abstract description 26
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 59
- 239000003550 marker Substances 0.000 claims abstract description 53
- 230000002357 endometrial effect Effects 0.000 claims abstract description 43
- 102000036639 antigens Human genes 0.000 claims abstract description 27
- 108091007433 antigens Proteins 0.000 claims abstract description 27
- 239000000427 antigen Substances 0.000 claims abstract description 26
- 210000004369 blood Anatomy 0.000 claims abstract description 18
- 239000008280 blood Substances 0.000 claims abstract description 18
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 134
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 134
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 71
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 71
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 32
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 32
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 30
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 30
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 26
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 25
- 102100032912 CD44 antigen Human genes 0.000 claims description 23
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 23
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims description 22
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims description 22
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 22
- 238000002405 diagnostic procedure Methods 0.000 claims description 21
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 19
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 18
- 208000000450 Pelvic Pain Diseases 0.000 claims description 10
- 230000005906 menstruation Effects 0.000 claims description 9
- 102000049320 CD36 Human genes 0.000 claims description 7
- 108010045374 CD36 Antigens Proteins 0.000 claims description 7
- 239000013610 patient sample Substances 0.000 claims description 6
- WSFSSNUMVMOOMR-DICFDUPASA-N dideuteriomethanone Chemical compound [2H]C([2H])=O WSFSSNUMVMOOMR-DICFDUPASA-N 0.000 claims 7
- 210000004027 cell Anatomy 0.000 description 32
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 12
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 12
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 210000005168 endometrial cell Anatomy 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000002357 laparoscopic surgery Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 230000027758 ovulation cycle Effects 0.000 description 6
- 210000004696 endometrium Anatomy 0.000 description 5
- 238000002350 laparotomy Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 238000007477 logistic regression Methods 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 210000003567 ascitic fluid Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102100029880 Glycodelin Human genes 0.000 description 2
- 101000585553 Homo sapiens Glycodelin Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- QEJQAPYSVNHDJF-UHFFFAOYSA-N $l^{1}-oxidanylethyne Chemical compound [O]C#C QEJQAPYSVNHDJF-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 101100042683 Arabidopsis thaliana SLAC1 gene Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101100334524 Homo sapiens FCGR3B gene Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 1
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 1
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010065951 Retrograde menstruation Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 101000870345 Vasconcellea cundinamarcensis Cysteine proteinase 1 Proteins 0.000 description 1
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108700023468 protein-bound SN-C polysaccharide Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000009810 tubal ligation Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Devices That Are Associated With Refrigeration Equipment (AREA)
- Measurement Of Mechanical Vibrations Or Ultrasonic Waves (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11703199P | 1999-01-25 | 1999-01-25 | |
| US60117031 | 1999-01-25 | ||
| PCT/CA2000/000060 WO2000043789A1 (en) | 1999-01-25 | 2000-01-24 | Method and diagnostic kit for diagnosis of endometriosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2088800A true AU2088800A (en) | 2000-08-07 |
Family
ID=22370639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU20888/00A Abandoned AU2088800A (en) | 1999-01-25 | 2000-01-24 | Method and diagnostic kit for diagnosis of endometriosis |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1147421B1 (enExample) |
| JP (1) | JP2002535658A (enExample) |
| AT (1) | ATE374370T1 (enExample) |
| AU (1) | AU2088800A (enExample) |
| BR (1) | BR0007702A (enExample) |
| CA (1) | CA2359200A1 (enExample) |
| DE (1) | DE60036536T2 (enExample) |
| ES (1) | ES2292424T3 (enExample) |
| NZ (1) | NZ513692A (enExample) |
| WO (1) | WO2000043789A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003244815A1 (en) * | 2002-02-13 | 2003-09-04 | Metriogene Biosciences Inc. | Cd16b as a marker for the diagnosis of endometriosis |
| US20050100967A1 (en) * | 2003-07-11 | 2005-05-12 | Science & Technology Corporation @ Unm | Detection of endometrial pathology |
| US20060008876A1 (en) | 2004-07-07 | 2006-01-12 | Shami A S E | ME-5, ME-2, and EPP2: human protein antigens reactive with autoantibodies present in the serum of women suffering from endometriosis |
| EP1931993A2 (en) * | 2005-09-14 | 2008-06-18 | Medizinische Universität Wien | Means and methods for diagnosing endometriosis |
| DE102012002929A1 (de) | 2012-02-14 | 2013-08-14 | Jürgen Lewald | Minimalinvasives Verfahren für die Diagnose und die Therapieverlaufskontrolle der Endometriose |
| WO2017039751A1 (en) | 2015-08-28 | 2017-03-09 | Bioincept, Llc | Mutant peptides and methods of treating subjects using the same |
| EP3215847A4 (en) * | 2014-11-03 | 2018-02-14 | Bioincept LLC | Pif binding as a marker for immune dysregulation |
| CA2996874A1 (en) | 2015-08-28 | 2017-03-09 | Bioincept, Llc | Compositions and methods for the treatment of neurodamage |
| CN113994208A (zh) * | 2019-04-26 | 2022-01-28 | 中外制药株式会社 | 子宫内膜异位症的诊断方法、疾病状态监测方法和试剂盒 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03202769A (ja) * | 1989-03-07 | 1991-09-04 | Adeza Biomedical Corp | 子宮内膜症診断の方法及び試薬 |
| US5618680A (en) * | 1994-12-28 | 1997-04-08 | Institut De Medecine De La Reproduction De Montreal | Use of ligands specific to major histocompatibility complex-class I antigens for diagnosing endometriosis |
| JP2001501300A (ja) * | 1996-09-06 | 2001-01-30 | オステオメーター・ビオテク・エー／エス | ヒト子宮内膜の生化学的マーカー |
-
2000
- 2000-01-24 BR BR0007702-0A patent/BR0007702A/pt not_active IP Right Cessation
- 2000-01-24 CA CA002359200A patent/CA2359200A1/en not_active Abandoned
- 2000-01-24 AU AU20888/00A patent/AU2088800A/en not_active Abandoned
- 2000-01-24 AT AT00901009T patent/ATE374370T1/de not_active IP Right Cessation
- 2000-01-24 EP EP00901009A patent/EP1147421B1/en not_active Expired - Lifetime
- 2000-01-24 WO PCT/CA2000/000060 patent/WO2000043789A1/en not_active Ceased
- 2000-01-24 NZ NZ513692A patent/NZ513692A/en not_active IP Right Cessation
- 2000-01-24 ES ES00901009T patent/ES2292424T3/es not_active Expired - Lifetime
- 2000-01-24 DE DE60036536T patent/DE60036536T2/de not_active Expired - Lifetime
- 2000-01-24 JP JP2000595159A patent/JP2002535658A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE374370T1 (de) | 2007-10-15 |
| BR0007702A (pt) | 2002-09-10 |
| EP1147421A1 (en) | 2001-10-24 |
| WO2000043789A1 (en) | 2000-07-27 |
| EP1147421B1 (en) | 2007-09-26 |
| NZ513692A (en) | 2001-09-28 |
| CA2359200A1 (en) | 2000-07-27 |
| JP2002535658A (ja) | 2002-10-22 |
| DE60036536D1 (de) | 2007-11-08 |
| ES2292424T3 (es) | 2008-03-16 |
| DE60036536T2 (de) | 2008-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weinberg et al. | Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation | |
| Florian et al. | Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes | |
| Sonneck et al. | Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome | |
| Camilleri-Broet et al. | Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations | |
| Brooks et al. | Expression of the CD15 antigen (Lewis x) in breast cancer | |
| Gagné et al. | Development of a nonsurgical diagnostic tool for endometriosis based on the detection of endometrial leukocyte subsets and serum CA-125 levels | |
| US6743595B1 (en) | Method and diagnostic kit for diagnosis of endometriosis | |
| JPH06505332A (ja) | 総白血球表面抗原を用いた治療法及び診断法 | |
| Jorizzo et al. | Bowel-associated dermatosis-arthritis syndrome: Immune complex-mediated vessel damage and increased neutrophil migration | |
| Gagné et al. | Blood leukocyte subsets are modulated in patients with endometriosis | |
| Richter et al. | HLA-DR expression in acute pancreatitis | |
| AU2088800A (en) | Method and diagnostic kit for diagnosis of endometriosis | |
| Pavlov et al. | Characterization of cytokine production by human term placenta macrophages in vitro | |
| Kilmartin et al. | CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis | |
| Hodge et al. | Surface activation markers of T lymphocytes: role in the detection of infection in neonates | |
| Ushiwaka et al. | Peritoneal natural killer cell chemotaxis is decreased in women with pelvic endometriosis | |
| Ergun et al. | Systemic immune-inflammation index as a potential biomarker for assessing disease activity and predicting proteinuria development in systemic lupus erythematosus | |
| Kuryliszyn-Moskal et al. | Circulating intercellular adhesion molecule 1 in rheumatoid arthritis—relationship to systemic vasculitis and microvascular injury in nailfold capillary microscopy | |
| Eberwein et al. | Conjunctival HLA-DR and CD8 expression detected by impression cytology in ocular graft versus host disease | |
| WO1997020217A9 (en) | Method for diagnosing autoimmune diseases | |
| US20030219835A1 (en) | CD16b as a marker for the diagnosis of endometriosis | |
| Gulan et al. | Systemic and local expression of perforin in lymphocyte subsets in acute and chronic rheumatoid arthritis. | |
| Li et al. | A low level of plasmacytoid dendritic cells at engraftment is a valuable prognostic indicator in children receiving allogeneic hematopoietic stem cell transplantation | |
| Fuggle | Immunophenotypic analysis of leukocyte infiltration in the renal transplant | |
| CN113832222A (zh) | 生物标志物在制备用于诊断流产的试剂盒中的用途 |